Multi-Analyte Profiles (MAPs) developed by Myriad/ Rules Base Medicine (RBM) provide a comprehensive evaluation of the proteome response to disease, drugs, and the environment in laboratory animals. Markers of cancer, infectious disease, autoimmunity, cardiovascular risk, as well as hormones, cytokines/chemokines, and acute phase reactants are measure from a single low volume sample. Currently RBM is the only company with the ability to measure multiple proteins per sample. Also there are compatibility issues with previous research and studies.

Bid Protests Not Available